Pharmaceutical Manufacturers Association
Executive Summary
C. Vance Gordon, PhD, named Assistant VP-R&D, replacing Charles Cleveland, who is retiring from the association Feb. 1. An analyst in the Office of the Assistant Secretary of Defense for Program Analysis and Evaluation since 1985, Gordon has been responsible for integrating health programs into DoD planning priorities. From 1981-1985, he was director of medical mobilization and planning in the Office of the Assistant Secretary for Health Affairs.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.